Programmed death ligand‐1 expression as immunotherapeutic target in sinonasal cancer

Programmed death ligand‐1 expression as immunotherapeutic target in sinonasal cancer INTRODUCTIONTumors in the sinonasal cavities represent 5% of all head and neck cancers with an incidence of approximately 0.5 of 100 000 inhabitants. Squamous cell carcinoma (SCC) and intestinal‐type adenocarcinoma (ITAC) represent approximately 70%‐80% of sinonasal cancer, the remainder include a miscellany of neuroendocrine carcinomas, neuroectodermal neoplasms, salivary gland tumors, and undifferentiated carcinomas. Sinonasal SCC and ITAC have been etiologically related to occupational exposures, including wood and leather dust, nickel, and chromium. There are also indications that human papillomavirus (HPV) and Epstein‐Barr virus play a role in the development of a subset of sinonasal cancer. Diagnosis of these tumors is often late due to unspecific symptoms similar to inflammatory processes.Despite improvements in the field of surgery and radiotherapy, the prognosis is still poor with a 5‐year overall survival of 30%‐50%. Typically, all sinonasal tumors frequently develop local recurrences (50%‐80%), the main cause of death. Lymph node or distant metastasis occur in 10%‐20% of cases. For locally advanced sinonasal tumors, treatment usually is surgery combined with radiotherapy, and, in some cases, a multimodal approach, including chemotherapy. However, there is a clear need for new therapeutic options.Molecular genetic studies may guide the application of modern anticancer drugs that target specific signaling pathways. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Head & Neck: Journal for the Sciences & Specialties of the Head and Neck Wiley

Loading next page...
 
/lp/wiley/programmed-death-ligand-1-expression-as-immunotherapeutic-target-in-fOAvgWHrUu
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
© 2018 Wiley Periodicals, Inc.
ISSN
1043-3074
eISSN
1097-0347
D.O.I.
10.1002/hed.25067
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONTumors in the sinonasal cavities represent 5% of all head and neck cancers with an incidence of approximately 0.5 of 100 000 inhabitants. Squamous cell carcinoma (SCC) and intestinal‐type adenocarcinoma (ITAC) represent approximately 70%‐80% of sinonasal cancer, the remainder include a miscellany of neuroendocrine carcinomas, neuroectodermal neoplasms, salivary gland tumors, and undifferentiated carcinomas. Sinonasal SCC and ITAC have been etiologically related to occupational exposures, including wood and leather dust, nickel, and chromium. There are also indications that human papillomavirus (HPV) and Epstein‐Barr virus play a role in the development of a subset of sinonasal cancer. Diagnosis of these tumors is often late due to unspecific symptoms similar to inflammatory processes.Despite improvements in the field of surgery and radiotherapy, the prognosis is still poor with a 5‐year overall survival of 30%‐50%. Typically, all sinonasal tumors frequently develop local recurrences (50%‐80%), the main cause of death. Lymph node or distant metastasis occur in 10%‐20% of cases. For locally advanced sinonasal tumors, treatment usually is surgery combined with radiotherapy, and, in some cases, a multimodal approach, including chemotherapy. However, there is a clear need for new therapeutic options.Molecular genetic studies may guide the application of modern anticancer drugs that target specific signaling pathways.

Journal

Head & Neck: Journal for the Sciences & Specialties of the Head and NeckWiley

Published: Jan 1, 2018

Keywords: ; ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off